Linda has worked both in early stage and large company environments, including 13 years with Merck and Company in roles spanning manufacturing, clinical research and drug development, public and investor relations, fund raising, marketing and business development.
Most recently Linda served as a global team leader at PAREXEL, a contract research organization developing strategic partnerships with pharmaceutical companies to support their needs to expedite clinical development to get important treatments to market.
“We are thrilled to have someone with Linda’s breadth of industry experience join the team,” said BioNJ President and CEO Debbie Hart. “As Vice President of Engagement, Linda will use her diverse experience in the life sciences industry to develop new opportunities, partnerships and programs that will foster a stronger life sciences community within New Jersey and enhance the development of new, innovative therapies and cures.”
Linda can be reached at LBrown@BioNJ.org or at 609-890-3185.
BioNJ, The Gateway to Health, is a powerful network of 400 Member Investors representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t WaitSM, BioNJ is committed to the growth and prosperity of New Jersey’s life sciences ecosystem to help accelerate the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society. As the industry’s voice in New Jersey, we fulfill our Mission to help our Members help Patients by driving capital formation and fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.
For more information on BioNJ, please visit www.BioNJ.org.